A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients

Trial Profile

A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Eribulin (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Korea
  • Most Recent Events

    • 12 Mar 2018 Planned End Date changed from 1 May 2018 to 1 Sep 2018.
    • 12 Mar 2018 Planned primary completion date changed from 1 May 2018 to 1 Sep 2018.
    • 21 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top